Under the Paperwork Reduction Act of 1995, no persons are required

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 GFR 1.99)

Application Number		10675783		
Filing Date		2003-09-30		
First Named Inventor	Levine et al.			
Art Unit		2182		
Examiner Name	Unknown			
Attorney Docket Number		AUS920030496US1		

				, and the	,	not realison	710002200001001	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
					U.S.I	PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Da	Date Name of Patentee or Applicant of cited Document		Releva	Columns, Lines int Passages or s Appear		
	1	6944720	B2	2005-09-	13	Sperber et al.				
	2	7035996	B2	2006-04-2	25	Woodall et al.				
If you wish	n to ac	dd additional U.S. Pater	nt citatio	n informat	tion pl	ease click the	Add button.		Add	
-			U.S.P	ATENT A	PPLK	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date			Releva	Columns,Lines on Passages or s Appear		
	1	20040030870	A1	2004-02-	12	Buser				
If you wish	n to ac	l dd additional U.S. Publi	shed Ap	plication o	itation	n information p	please click the Ad	d button	Add	
				FOREIGN	N PAT	ENT DOCUM	IENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Gind Code4	Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns, where Relevant Passages or Rele igures Appear	-
	1									
If you wish	n to a	dd additional Foreign P	atent Do	cument ci	itation	information p	lease click the Add	button	Add	
						RATURE DO			Remove	
			NOP	-PAIENI	ш	KATURE DU	CUMENIS		rtemove	

	Application Number		10675783	
	Filing Date		2003-09-30	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Levir		ine et al.	
(Not for submission under 37 CFR 1.99)	Art Unit		2182	
(Examiner Name Unkn		known	
	Attorney Docket Number		AUS920030486US1	

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	Ţ5	
	1			

If you wish to add additional non-patent literature document citation information please click the Add button Add

Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTIO Patent Documents at year USPTIO_CODY or MPEP 901.04. 2 Either office that issued the document, by the bro-bitter code (WIPO Standard ST.3). 3 For disparence patient bounders, by exaction of the year of the Emperor most procedule has early a time-for office patient bounders. If which office the properties with the properties are indicated on the document under WIPO Standard ST.16 if possible. 3 Applicant is to place a check mark here if English tanguage branisation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10675783		
Filing Date		2003-09-30		
First Named Inventor	Levine et al.			
Art Unit		2182		
Examiner Name	Unknown			
Attorney Docket Number		AUS920030486US1		

CERTIFICATION STATEMENT

Please see 37	CFR 1.97 at	nd 1.98 to make the	appropriate selection(s):
---------------	-------------	---------------------	---------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information siclosure statement. See 37 CFR 197(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to [2] any individual designated in 37 CFR 1.58(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.59(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.59(c) more than three months prior to the filing of the information disclosure

See attached certification statement.

Fee set forth in 37 CFR 1,17 (p) has been submitted herewith.

□ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Gerald H. Glanzman/	Date (YYYY-MM-DD)	2006-08-03					
Name/Print	Geraid H. Glanzman	Registration Number	25035					

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2213.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.